Genscript Biotech Corporation
金斯瑞生物科技股份有限公司 *
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE

Reference is made to the announcements of Genscript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") dated 22 December 2017, 1 November 2018, 4 December 2018, 4 April 2019, 16 April 2019, 28 August 2019 and 7 November 2019. The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the U.S. Food and Drug Administration ("**FDA**") has granted a Breakthrough Therapy Designation ("**BTD**") to Janssen Research & Development, LLC ("**Janssen**") for JNJ-68284528 ("**JNJ-4528**"), an investigational B-cell maturation antigen ("**BCMA**") targeted chimeric antigen receptor ("**CAR**") T-cell therapy in previously treated patients with multiple myeloma.

Initial results for JNJ-4528 from the U.S. Phase 1b/2 CARTITUDE-1 (MMY2001, NCT03548207) study will be presented at the 61st American Society of Hematology Annual Meeting ("**ASH**") in Orlando, Florida, the USA, which is expected to take place from 7 December to 10 December 2019. The BTD for JNJ-4528 is based on the Phase 1b CARTITUDE-1 study.

The BTD process is designed to expedite the development and review of therapies that are intended to treat a serious condition, where preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over available therapies on a clinically significant endpoint(s).

In December 2017, Legend Biotech, USA Inc. and Legend Biotech Ireland Limited ("**Legend**"), subsidiaries of GenScript Biotech Corporation entered into a worldwide collaboration and license agreement with Janssen, to jointly develop and commercialize, LCAR-B38M/JNJ-4828 in multiple myeloma. (JNJ-4528 identifies the investigational product being studied in the US and Europe, and LCAR-B38M identifies the investigational product in China which are representative of the same CAR-T cell therapy.) LCAR-B38M/JNJ-4528 is a structurally differentiated CAR-T cell therapy containing a 4-1BB co-stimulatory domain and two BCMA-targeting single domain antibodies designed to confer avidity.

The Company believes that the grant of BTD by the FDA for JNJ-4528 marks an important regulatory milestone, as Legend, together with Janssen, continues the quest to provide a new therapy for patients with multiple myeloma. We also believe that such grant may be an indication of the recognition of the unmet need of the therapy, which may expedite future development of such therapy.

For details in relation to CARTITUDE-1, please refer to the voluntary announcement of the Company dated 7 November, 2019.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise in caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 8 December 2019

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* *For identification purposes only*